CLP, OTCCNLF) has begun dosing patients in a new arm of its ongoing phase II trial, exploring an updated method for delivering its next-generation cancer immunotherapy for advanced melanoma. Known as Cohort 4, the study will assess intradermal administration and an accelerated dosing schedule of Scancell's iSCIB1+ Immunobody therapy, which is designed to stimulate the immune system to attack tumours. 